Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

New England Journal of Medicine

Volumn 336, Issue 10, 1997, Pages 683-690

  Koh, Kwang Kon ^a   Mincemoyer, Rita ^a   Bui, Minh N ^a   Csako, Gyorgy ^b   Pucino, Frank ^b   Guetta, Victor ^a   Waclawiw, Myron ^a   Cannon III, Richard O ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; LIPIDS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0009060192     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199703063361002     Document Type: Article

References (45)

1. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
3. Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12:259-85.
4. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
5. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
6. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69:381-7.
7. Lupu F, Bergonzelli GF, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090-100.
8. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-9.
9. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC Study. Circulation 1995;91:284-90.
10. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989;10:77-82.
11. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-8.
12. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
13. Cortellaro M, Cofrancesco E, Boschetti C, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993;13:1412-7.
14. Ridker PM, Hennekens CH, Stampfer MJ, Manson JK, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-3.
15. Keber I, Keber D. Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. Haemostasis 1992;22:187-94.
16. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen I, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
17. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
18. Sporrong T, Mattson LA, Samsioe G, Stigendal L, Hellgren M. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990;97:939-44.
19. van Wersch JWJ, Ubachs JMH, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. Eur J Clin Chem Clin Biochem 1994;32: 449-53.
20. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420-3.
21. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-5.
22. Daly E, Vessey MP, Hawkins MM, Carson IL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
23. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
24. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Levine DM, Sloan B-J, Donner JE, Lorenz JD, Heinzerling RH. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 1992;22:173-8.
27. Declerck TJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-5.
28. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res 1989;6:67-75.
29. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
30. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
31. Shahar E, Folsom AR, Salomaa VV, et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996;93:1970-5.
32. Scarabin P-Y, Plu-Bureau G, Bara L, Bonithon Kopp C, Guize L, Samama MM. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993;70:584-7.
33. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991; 266:2459-65.
34. Kugiyama K, Sakamoto T, Misumi I, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993;73:335-43.
35. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A 1991;88:9959-63. [Erratum, Proc Natl Acad Sci U S A 1992; 89:1148.]
36. Keaney JF Jr, Shwaery GT, Xu A, et al. 17 β-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994;89:2251-9.
37. Kooistra T. The use of cultured human endothelial cells and hepatocytes as an in vitro model system to study modulation of endogenous fibrinolysis. Fibrinolysis 1990;4:Suppl 2:33-9.
38. Quax PHA, van den Hoogen CM, Verheijen JH, et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990;265:15560-3.
39. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991;88:1346-53.
40. Beebe DP, Aronson DL. Turnover of human tissue plasminogen activator (tPA) in rabbits. Thromb Res 1986;43:663-74.
41. Korninger C, Stassen J-M, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemost 1981;46: 658-61.
42. 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1992;89:7427-31.
43. 2-macroglobulin receptor. Proc Natl Acad Sci U S A 1992;89:7422-6.
44. 2-macroglobulin receptor/LDL receptor-related protein binds urokinase•plasminogen activator inhibitor type-1 complex: evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-6.
45. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980;255:10464-71.